Johnson & Johnson (JNJ) to Withdraw the LINC Reflux Management System from Markets Outside the U.S.

Group 1 - Johnson & Johnson (JNJ) will withdraw the LINC Reflux Management System from markets outside the U.S. by the end of March 2026 for commercial reasons, while the device will remain available in the U.S. [2] - Guggenheim raised its price target on Johnson & Johnson from $167 to $206, citing strong top-line growth in 2025 despite the loss of exclusivity for Stelara [3] - The company’s recently launched bladder cancer drugs, Inlexzo (TAR-200) and TAR-210, are expected to generate over $6 billion in sales at peak [3] Group 2 - Johnson & Johnson operates across pharmaceuticals, medical devices, and consumer health markets, focusing on research and development, manufacturing, and sales of a broad range of healthcare products globally [4] - The company is recognized as one of the Best Diversified Stocks to buy according to hedge funds, indicating significant upside potential [1]